Specialty pharmaceutical company developing Erwinaze for the treatment of pediatric acute lymphocytic leukemia
EUSA was created in 2006 to build a trans-Atlantic speciality pharma company. EUSA acquired several clinical assets and successfully guided Erwinaze, a first-in-class product for the treatment of certain cancers in children, to approval in the US.
CEO Bryan Morton
Advent Contact Raj Parekh
Advent invested in the Series B financing in 2007. EUSA was acquired by Jazz Pharma in 2012 for $700m.
Exited Investments
FDA approves Erwinaze to treat a form of leukemia
Press Release. The U.S. Food and Drug Administration today approved Erwinaze (asparaginase Erwinia chrysanthemi) to treat patients with acute lymphoblastic leukemia (ALL), who have developed an allergy (hypersensitivity) to…
Read More
EUSA Pharma Announces FDA Approval Of Orphan Drug ERWINAZE™ For Treatment Of Acute Lymphoblastic Leukemia
Press Release. Langhorne, PA and Oxford, UK – 18 November 2011 – EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today…
Read More
EUSA Pharma to Acquire US Specialty Oncology Company Cytogen
Press Release. Acquisition of US infrastructure completes build of EUSA’s transatlantic commercialization platform $22.6 million acquisition expands EUSA’s product portfolio EUSA raises over $50 million to fund acquisition and…
Read More
EUSA Pharma out-licenses Preclinical-stage Human Antibody to GlaxoSmithKline for up to $44 million plus Royalities
Press Release. Doylestown PA, USA and Oxford, UK - 18 February 2008 – EUSA Pharma Inc (‘EUSA’), a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical…
Read More
Advent Venture Partners invests in $175m financing round for EUSA Pharma Inc, new transatlantic specialty pharmaceutical company
Press Release. Thursday 1 March 2007 - EUSA Pharma Inc, a new transatlantic specialty pharmaceutical company focused on developing and marketing products for the hospital market both in Europe…
Read More
